Indian drugmaker launches cancer drug in UK

Versavo is indicated for the treatment of various types of cancers

Dr. Reddy’s Laboratories has launched Versavo (bevacizumab) in the United Kingdom / Dr. Reddy's


Dr. Reddy’s Laboratories has launched Versavo (bevacizumab), a biosimilar of Roche’s cancer drug Avastin, in the United Kingdom. 

Versavo is indicated for the treatment of various types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer.

Dr. Reddy’s introduced Versavo in India in 2019. Following this, Versavo was launched in other markets including Thailand, Ukraine, Nepal, and Jamaica under the same brand name. In Colombia, however, the product was introduced under the brand name Persivia.

Jayanth Sridhar, global head of biologics at Dr. Reddy’s, said, “The launch of Versavo® in a highly regulated market underscores our capability for global clinical development of high-quality biosimilar products. Versavo is a potential treatment option for patients with different types of cancers. This launch reinforces our commitment to bring more biosimilar and other critical biological products to meet the unmet needs of patients, and strengthens our focus on oncology.”

Versavo marks the debut of Dr. Reddy’s biosimilar products in the UK. It comes in strengths of 100mg and 400mg single-use vials.

Dr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India, founded in 1984. With the mission "Good Health Can't Wait," it provides a range of products and services including APIs, generics, branded generics, biosimilars, and OTC medications. Its key therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.








E Paper